NICHE
Type 1 Diabetes
Key Facts
About Continuity Biosciences
Continuity Biosciences is an early-stage biotech innovator building a portfolio of precision drug delivery platforms designed to enhance the efficacy and safety of existing and emerging therapies. The company's core strategy involves creating implantable and localized systems—such as the NICHE platform for cell therapy and iontophoretic devices for targeted chemotherapy—that protect therapeutics and maximize impact at the disease site while minimizing systemic exposure. With a focus on significant unmet needs in Type 1 diabetes, pancreatic cancer, HIV, and other conditions, Continuity is positioning itself at the intersection of advanced engineering and deep biological insight. The company has secured strategic investment from Breakthrough T1D to advance its lead program toward human trials.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| Type I Diabetes | Genclis | Discovery |
| Inreda AP® | Inreda Diabetic | Commercial |